Form 13-F position report

LIFECORE BIOMEDICAL INC

Reported by 22NW LP

LFCR CUSIP 514766104 Manager CIK 0001694297

Reported 1,254 shares, unchanged from the prior quarter.

Reported value 32.7%; share count 0.0% vs. the prior quarter.

Unchanged
% of reported 13F value < 0.01% This manager · Q3 2026
Shares 1,254 Quarter-end amount reported
Reported value $8,251 Fair value at quarter end
Consecutive quarters held 22 Through Q3 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 13577000
2022-03-31 14173000
2022-06-30 13382000
2022-09-30 15603000
2022-12-31 11373443
2023-03-31 6634509
2023-06-30 16972407
2023-09-30 13251466
2023-12-31 10864447
2024-03-31 9319905
2024-06-30 24003976
2024-09-30 23652944
2024-12-31 31147294
2025-03-31 29820465
2025-06-30 22628281
2025-09-30 20147121
2025-12-31 23026213
2026-03-31 18866301
2026-06-30 6220
2026-09-30 8251

Quarterly position history

How this manager's reported quarter-end position changed over time.

20 quarters
Quarterly reported position history for LIFECORE BIOMEDICAL INC held by 22NW LP.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Unchanged 1,254 0 (0.0%) < 0.01% $8,251 2026-11-13
Q2 2026 Unchanged 1,254 0 (0.0%) < 0.01% $6,220 2026-08-14
Q1 2026 Unchanged 1,254 0 (0.0%) 12.93% $18,866,301 2026-05-15
Q4 2025 Unchanged 1,254 0 (0.0%) 9.69% $23,026,213 2026-02-13
Q3 2025 Reduced 1,254 -262,926 (-99.5%) 9.49% $20,147,121 2025-11-14
Q2 2025 Reduced 264,180 -1,490,981 (-84.9%) 14.25% $22,628,281 2025-08-14
Q1 2025 Unchanged 1,755,161 0 (0.0%) 20.0% $29,820,465 2025-05-14
Q4 2024 Unchanged 1,755,161 0 (0.0%) 19.65% $31,147,294 2025-02-14
Q3 2024 Unchanged 1,755,161 0 (0.0%) 19.83% $23,652,944 2024-11-14
Q2 2024 Unchanged 1,755,161 0 (0.0%) 20.48% $24,003,976 2024-08-14
Q1 2024 Unchanged 1,755,161 0 (0.0%) 8.03% $9,319,905 2024-05-15
Q4 2023 Unchanged 1,755,161 0 (0.0%) 7.08% $10,864,447 2024-02-14
Q3 2023 Unchanged 1,755,161 0 (0.0%) 9.44% $13,251,466 2023-11-14
Q2 2023 Unchanged 1,755,161 0 (0.0%) 10.6% $16,972,407 2023-08-14
Q1 2023 Unchanged 1,755,161 0 (0.0%) 4.08% $6,634,509 2023-05-15
Q4 2022 Unchanged 1,755,161 0 (0.0%) 6.14% $11,373,443 2023-02-10
Q3 2022 Added 1,755,161 +412,945 (30.8%) 8.82% $15,603,000 2022-11-14
Q2 2022 Added 1,342,216 +118,306 (9.7%) 7.1% $13,382,000 2022-08-12
Q1 2022 Added 1,223,910 +735 (0.1%) 5.15% $14,173,000 2022-05-13
Q4 2021 Added 1,223,175 +369,874 (43.3%) 4.2% $13,577,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

115 managers reported LIFECORE BIOMEDICAL INC for Q3 2026.

Managers reporting LIFECORE BIOMEDICAL INC in Q3 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
WYNNEFIELD CAPITAL INC Added 4,867,816 +164,600 26.3% $32,030,229 54 qtrs
Legion Partners Asset Management LLC Added 4,481,329 +19,506 100.0% $29,487,145 29 qtrs
325 CAPITAL LLC Unchanged 2,895,881 0 5.45% $19,054,897 12 qtrs
Greenhaven Road Investment Management L P Reduced 2,868,881 -321,888 14.57% $18,877,237 15 qtrs
BlackRock Inc Added 2,018,175 +5,082 < 0.01% $13,279,591 9 qtrs
VANGUARD CAPITAL MANAGEMENT LLC Unchanged 1,288,621 0 < 0.01% $8,479,126 3 qtrs
GEODE CAPITAL MANAGEMENT LLC Reduced 848,624 -6,876 < 0.01% $5,585,482 54 qtrs
MORGAN STANLEY Reduced 737,537 -31,823 < 0.01% $4,852,994 54 qtrs
STATE STREET CORPORATION Reduced 638,081 -29,950 < 0.01% $4,198,573 54 qtrs
Quinn Opportunity Partners LLC Added 539,450 +85,955 0.19% $3,549,581 11 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2026
Filed
November 13, 2026
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
1,254
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.